Beam Therapeutics Inc. (BEAM) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Beam Therapeutics Inc. (BEAM) closed at USD 23.65 on 2026-10-14, a change of -10.5 % over the past year, with a market capitalization of USD 2.55B.

Beam Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Beam Therapeutics Inc. key figures

Previous close

USD 23.65 (2026-10-14)

1-year change

-10.5 %

Market cap

USD 2.55B

Enterprise value

USD 1.57B

P/E ratio (trailing)

-36.37

P/E ratio (forward)

-5.22

EPS (trailing)

-0.68

EPS (forward)

-4.74

PEG ratio

n/a

Price to book

2.31

Revenue growth

-94.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

14.33

Employees

540

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Beam Therapeutics Inc.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Beam Therapeutics Inc. and compare it with other stocks.